Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...

According to Inan’s team: “There is no documented production process of atezolizumab biosimilar in the literature except one ...

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...

TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and Exchange ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report ...